International law firm Osborne Clarke has advised AlbionVC and Delin Ventures on their investment in health and research technology company uMed's £9.8 million Series A funding round. The investment enables uMed to boost researcher and patient participation in clinical trials. Other investors included Playfair Capital and Silicon Valley's 11.2 Capital.
Since its 2020 seed funding round, uMed’s technology has enabled a number of successful nationwide studies to take place across the UK, including a prospective precision medicine clinical trial for patients with high hypertension and a nationwide study into identifying risk of Parkinson’s Disease.
Osborne Clarke's international venture capital team is a go-to practice for companies operating in tech-enabled industries. From start-up through venture financing and the growth journey beyond, whether continuing to sale, IPO or international expansion, the team has an outstanding track record advising businesses, entrepreneurs and investors that are driving innovation. Osborne Clarke's dedicated resource centre, OC Ventures, brings together experts from across our international network to deliver a seamless service to clients throughout the ventures ecosystem.